Pharmaceutical Investing UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel)
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor